Hepatocyte growth factor in physiology and infectious diseases by Imamura Ryu & Matsumoto Kunio
Hepatocyte growth factor in physiology and
infectious diseases













Hepatocyte Growth Factor in Physiology and Infectious Diseases 
 
 
Ryu Imamura and Kunio Matsumoto 
 
Division of Tumor Dynamics and Regulation, 
Cancer Research Institute, Kanazawa University, 
Kakuma-machi, Kanazawa 920-1192, Japan 
 
Running title: HGF-Met pathway in infectious diseases 
 
Kew words: HGF, Met, regeneration, infectious diseases, hepatocyte growth factor 
 
Corresponding author: Kunio Matsumoto, Ph.D. 
 Cancer Research Institute, 
 Kanazawa University 
 Kakuma-machi, Kanazawa 920-1192, Japan 
 Tel: +81-76-264-6745 
 Fax: +81-76-234-4513 




Hepatocyte growth factor (HGF) is a pleiotropic cytokine composed of an α-chain and a β-
chain, and these chains contain four kringle domains and a serine protease-like structure, 
respectively. The receptor for HGF was identified as the c-met proto-oncogene product of 
transmembrane receptor tyrosine kinase. HGF-induced signaling through the receptor Met 
provokes dynamic biological responses that support morphogenesis, regeneration, and the 
survival of various cells and tissues, which includes hepatocytes, renal tubular cells, and 
neurons. Characterization of tissue-specific Met knockout mice has further indicated that the 
HGF–Met system modulates immune cell functions and also plays an inhibitory role in the 
progression of chronic inflammation and fibrosis. However, the biological actions that are 
driven by the HGF–Met pathway all play a role in the acquisition of the malignant 
characteristics in tumor cells, such as invasion, metastasis, and drug resistance in the tumor 
microenvironment. Even though oncogenic Met signaling remains the major research focus, 
the HGF–Met axis has also been implicated in infectious diseases. Many pathogens try to 
utilize host HGF–Met system to establish comfortable environment for infection. Their 
strategies are not only simply change the expression level of HGF or Met, but also actively 
hijack HGF–Met system and deregulating Met signaling using their pathogenic factors. 
Consequently, the monitoring of HGF and Met expression, along with real-time detection of 
Met activation, can be a beneficial biomarker of these infectious diseases. Preclinical studies 
designed to address the therapeutic significance of HGF have been performed on 
injury/disease models, including acute tissue injury, chronic fibrosis, and cardiovascular and 
neurodegenerative diseases. Likewise, manipulating the HGF–Met system with complete 
control will lead to a tailor‐made treatment for those infectious diseases. 
  
	 3 
The HGF-Met signaling pathway 
 
Hepatocyte growth factor (HGF) was originally identified and molecularly cloned as a 
mitogenic protein for hepatocytes in culture [1,2]. HGF is identical to the scatter factor, a 
fibroblast-derived factor that promotes the dispersal of sheets of epithelial cells [3,4], and a 
fibroblast-derived epithelial morphogen that induces the branching tubulogenesis of epithelia 
grown in three-dimensional cultures [5]. Thus, HGF is a unique growth factor that elicits 
multiple cellular responses including mitogenesis, cell motility and morphogenesis. These 
early findings implicated biological and pathophysiological roles for HGF in epithelial wound 
healing, tissue regeneration, tumorigenesis, and cancer invasion. 
The receptor for HGF was identified as the c-met proto-oncogene product of 
transmembrane receptor tyrosine kinase (RTK) in 1991 [6,7]. Historically, Met was first 
identified as the product of a human oncogene, Tpr-Met [8,9]. Tpr-Met was generated 
following a chromosomal rearrangement induced by the treatment of a human osteogenic 
sarcoma cell line with the carcinogen N-methyl-N’-nitronitrosoguanidine. This genomic 
rearrangement fuses two genetic loci. These include the translocated promoter region from 
chromosome 1q25, which encodes a dimerization leucine zipper motif, and MET from 
chromosome 7q31, which contributes the kinase domain and C terminus of the Met. Tpr-Met 
is a prototype for RTK-derived oncogenes generated following chromosomal translocation.  
Mice lacking HGF die in utero 13.5-15.5 days after post-gestation, and this is 
characterized by the impaired development of the placenta in many epithelial organs, 
particularly the liver [10]. Mice lacking the Met gene also show embryonic lethality and liver 
pathology [11]. Moreover, HGF provides spatially defined chemoattractant-like motogenic 
signals for myogenic precursor cells. The migration of myogenic precursor cells from the 
dermo-myotome in the somite to the limb buds and diaphragm is impaired in Met−/− mice. 
With this condition, the skeletal muscles of the limbs and diaphragm are not formed in mutant 
mice [12].  
Moreover, the definitive roles of the HGF–Met pathway in tissue protection and repair 
have been demonstrated using a conditional ablation of the Met gene in mice (Table 1). 
Characterization of these tissue-specific Met knockout mice has indicated that the HGF-Met 
system plays a promoting role in the regeneration, protection, and homeostasis of tissues, but 
it also plays an inhibitory role in the progression of chronic inflammation and fibrosis. 
However, the biological actions that are driven by the HGF–Met pathway all play a role in the 
acquisition of the malignant characteristics in tumor cells—invasion, metastasis, and drug 
resistance in the tumor microenvironment (Fig. 1). 
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Contrary to the relationship between many cytokines and their receptors, the 
relationship between HGF and Met is considered bi-unique; HGF is the only ligand for Met, 
and Met is the only receptor for HGF. Exceptionally and interestingly, Listeria 
monocytogenes surface protein Internalin B (InlB) is known to bind to the extracellular 
domain of Met and to induce the “scattering” of epithelial cells for bacterial entry [34]. A 
recent report have noted that Leukocyte Cell-Derived Chemotaxin 2 (Lect2), which is an 
identical molecule to chondromodulin-II (ChM-II), binds to the α-chain of the Met receptor 
and inhibits Met activation [35]. 
HGF belongs to a unique group of plasminogen-related growth factors/cytokines [36]. 
This group originated because of a divergent evolution from an ancestral gene that gave rise 
to a number of plasma proteins with serine proteinase activity, which includes plasminogen, 
urokinase- and tissue-type plasminogen activators (u-PA, t-PA), and prothrombin [36–39]. 
HGF is a glycosylated protein composed of α- and β-chains linked by one disulfide bridge 
[1,2] (Fig. 2A). The α-chain contains an N-terminal hairpin loop and four kringle domains (a 
cysteine-rich, double-looped structure involved in protein-protein interactions that is found in 
coagulation factors), while the β-chain harbors a serine protease homology domain that is 
inactive due to the loss of catalytic residue [40]. HGF is biosynthesized in a prepro-form, 
including a signal sequence and both α- and β-chains. HGF lost its proteinase activity to 
evolution, but retained the requirement for proteolytic processing. After cleavage of a signal 
peptide of the first 31 amino acids and extracellular secretion, a single-chain HGF is further 
cleaved between Arg494 and Val495 by serine proteases such as HGF-activator, matriptase, 
and hepsin [41,42]. Mature HGF is composed of 697/692 amino acids. HGF binds to sulfated 
glycosaminoglycans such as heparan sulfate and dermatan sulfate thus accumulates in the 
extracellular matrix [43–45]. 
HGF and Met show a unique expression pattern. HGF is expressed mainly in 
mesenchyme-derived cells such as fibroblasts and smooth muscle cells, whereas Met 
expression predominantly occurs in epithelial cells. This different feature facilitates a 
paracrine mode of signaling that promotes mitogenesis, motogenesis, morphogenesis, wound 
healing, and tissue regeneration [46]. On the other hand, an autocrine mode of HGF-Met 
signaling has also been found in mesenchymal stem cells and cancer cells [47–52]. 
Like HGF, the HGF receptor Met is synthesized as a 190 kDa glycosylated precursor 
that contains an extracellular ligand-binding region, a single-pass transmembrane segment, 
and a catalytic cytoplasmic region. Met is composed of structural domains that include the 
following domains: extracellular Sema (the domain found in semaphorin receptors), the PSI 
(the domain found in plexins, semaphorins and integrins), four IPTs (the domain found in 
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immunoglobulins, plexins, and transcription factors), the transmembrane, the intracellular 
juxtamembrane, and tyrosine kinase [53] (Fig. 2B). During biosynthetic transport, Met is 
cleaved within the Sema domain by intracellular endoproteases to generate a 50 kDa α-chain 
that has a completely extracellular location and a 145 kDa β-chain that contains the rest of the 
precursor protein. The Sema domain serves as a key element for ligand binding [54], while 
the involvement of IPT-3 and IPT-4 in the binding to HGF was demonstrated by another 
approach [55]. Most of the cells respond to HGF at the expression levels around 200 ~ 1500 
Met molecules per cell. 
The binding of HGF to Met results in the phosphorylation of multiple tyrosine residues 
within the cytoplasmic region. The phosphorylation of Tyr1234 and Tyr1235 within the 
tyrosine kinase domain positively regulates the catalytic activity of tyrosine kinase, and the 
subsequent phosphorylation of C-terminal tyrosine residues Tyr1349 and Tyr1356 recruits 
intracellular signaling molecules, including growth factor receptor-bound protein 2 (Grb2), 
GRB2-associated-binding protein 1 (Gab1), phosphoinositide 3-kinase (PI3-K), SH2 
containing protein tyrosine phosphatase (Shp2), phospholipase Cγ1 (PLCγ1), and signal 
transducers and activators of transcription-3 (Stat3). Typical biological activities evoked by 
Met activation include the promotion of mitogenesis and migration, suppression of cell death, 
and the induction of epithelial morphogenesis. Among the signaling molecules, Gab1 plays a 
critical role in HGF–Met pathway-dependent biological responses [56,57]. Gab1 is a 
scaffolding adaptor that contains the Met-binding site, by which a direct and robust 
interaction between Gab1 and Met results in prolonged Gab1 phosphorylation in response to 
HGF. The association of Gab1 and Met is responsible for the unique biological activities of 
HGF, including epithelial tubulogenesis.  
The promotion of cell survival (i.e., suppression of cell death) is a key biological action 
of the HGF–Met pathway in development, regeneration, and therapeutics. The activation of 
Met induces the phosphorylation of PI3-K and Akt, and the Akt-induced phosphorylation of 
Bad inhibits its pro-apoptotic activity (Fig. 3). In parallel, HGF increases the expression of 
anti-apoptotic Bcl-xL, by which the pro-apoptotic activity of Bax and Bim is inhibited 
[58,59]. Fas and Fas-ligand play a marked role in the induction of apoptosis. Another anti-
apoptotic mechanism involves an extracellular interaction between the extracellular domain of 
Met and the death receptor Fas [60]. The binding of HGF to Met prevents a functional 
association between Fas and Fas-ligand, therefore inhibiting the self-aggregation of Fas, a key 
event required for the induction of Fas-mediated apoptosis. In addition, the intracellular 
cytoplasmic tail of Met has evolved harboring a tandem pair of caspase-3 cleavage sites, 
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which bait, trap, and disable the active site of caspase-3, thereby blocking the execution of 
apoptosis [61]. 
The cytoplasmic juxtamembrane domain negatively regulates Met-dependent signal 
transduction. Cbl ubiquitin ligase binds phosphorylated Y1003, and this Cbl binding results in 
Met ubiquitination and degradation [62]. The suppressor of cytokine signaling 1 (SOCS1) 
also interacts with Met via its SH2 domain and promotes a turnover of Met. This process is 
dependent on the poly-ubiquitination of Met, but it is independent of Y1003 residue and Cbl 
[63]. The phosphorylation of Ser985 in the juxtamembrane domain also regulates Met 
activation. Ser985 is phosphorylated either by protein kinase-C (PKC) or type II cGMP-
dependent protein kinase G (PKG II), and when Ser985 is phosphorylated, HGF-dependent 
Met tyrosine phosphorylation and subsequent biological responses are suppressed [64–66]. 
The physiological and pathological roles of the HGF-Met pathways and the ongoing 
efforts for therapeutic manipulation of the HGF-Met signaling axis have been discussed in 
many excellent reviews [67–73]. Here, we focus on the role of the HGF-Met pathway in 
infectious diseases. 
 
HGF-Met system for malaria infection 
Plasmodium, the causative agent of malaria, first infects hepatocytes to initiate a 
mammalian infection. Sporozoites migrate through several hepatocytes by breaching their 
plasma membranes before infection is established in one of them. The wounding of 
hepatocytes by sporozoite migration is known to induce the secretion of HGF, which renders 
hepatocytes susceptible to infection [74]. Leirião et al. further demonstrated that the HGF-Met 
signaling requirement for infection is mediated by its anti-apoptotic signal effects through 
both PI3-K/Akt and, to a lesser extent, MAPK pathways [75]. These findings may explain 
why severe malaria cases are more frequent in hepatitis B virus carriers, who have higher 
HGF levels, than in controls, and it also explains the mechanism for the therapeutic effect of 
vitamin A in malaria infection, in part because of the inhibition of HGF production by 
retinoic acid, a metabolite of vitamin A. 
The study of human malaria liver-stage biology in vitro is hampered by the low 
infection efficiency of human hepatocellular carcinoma lines (<0.1%). HC-04 is a novel 
human hepatocellular carcinoma line that is the only established cell line that supports 
complete development of human malaria parasites [76]. Tao et al. used online two-
dimensional liquid chromatography tandem mass spectrometry to quantify protein expression 
profiles in HC-04 pre-/post-HGF treatment [77]. The proteomic data and correlative 
approaches identified several expected markers associated with epithelial-mesenchymal 
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transition, and, paradoxically, it also identified markers indicative of an epithelial phenotype 
following HGF treatment. HC-04s are subject to the influence of HGF, but the response is 
tempered by the up-regulation of proteins that are driving the maintenance of residual 
epithelial characteristics, which results in a more hepatocyte-like nature. Fine control of the 
epithelial-mesenchymal transition stages through HGF stimulation is probably required for an 
appropriate infection by malaria parasites. 
 
Helicobacter pylori infection and Met signaling 
Helicobacter pylori (H. pylori) chronically infects the stomachs of at least half the 
world’s population, and numerous studies have indicated that the persistent presence of this 
bacterium in a host increases their risk of several gastric diseases, which includes gastric 
adenocarcinoma [78,79]. H. pylori virulence factors differentially interfere with signaling 
pathways in gastric epithelial cells [80]. One well established H. pylori virulence factor is the 
presence of a cluster of about 30 genes, known as the cag pathogenicity island (cag PAI). The 
cag PAI encodes a type IV secretion system (T4SS), which is a multi-molecular complex that 
mediates the translocation of bacterial factors into the host cell [81,82]. CagA, a major H. 
pylori virulence factor that is produced by most strains of this species, is secreted via the 
T4SS into gastric epithelial cells, where it plays a pivotal role in the etiology of H. pylori-
associated gastric diseases [79,83].  
Churin et al. demonstrated that H. pylori infection activates Met and induces a 
motogenic response. They further showed that CagA binds Met and deregulates Met 
downstream signaling, which could be responsible for cancer onset and tumor progression 
[84] (Fig. 4). Oliveira et al. also showed how H. pylori strains with a functional T4SS induces 
an increase in Met tyrosine phosphorylation and in MMP-2 and MMP-9 activity. This could 
lead to extracellular matrix degradation and a subsequent invasion of cancer cells, suggesting 
a role for H. pylori in the later stages of gastric carcinogenesis [85]. They further 
demonstrated that E-cadherin plays a protective role in H. pylori-induced cell invasive 
phenotypes [86]. They found that H. pylori decreased the phosphorylation levels of Met in E-
cadherin–catenin functional cell lines. Also, depending on the E-cadherin status, infection 
with H. pylori has different effects on the tyrosine phosphorylation of p120-catenin. H. pylori 
alters the E-cadherin–catenin complex, leading to the formation of a multiprotein complex 
composed of CagA, Met, E-cadherin, and p120-catenin. This complex abrogates Met and 
p120-catenin tyrosine phosphorylation and consequently suppresses the cell-invasive 
phenotype induced by H. pylori. 
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Once within gastric epithelial cells, some CagA molecules are tyrosine-phosphorylated 
by the Src/Abl kinase. Although the importance of CagA phosphorylation has been studied 
intensively, recently accumulating information suggests that nonphosphorylated CagA also 
contributes to the development of H. pylori-associated gastric illnesses, which includes gastric 
cancer [87,88]. Suzuki et al. showed that nonphosphorylated CagA is involved in interacting 
with activated Met, leading to the sustained activation of PI3-K/Akt signaling in response to 
H. pylori infection. This in turn leads to the activation of β-catenin and to NF-κB signaling, 
which promotes proliferation and inflammation, respectively [89]. 
Various tumors are known to overexpress Met, which leads to shedding. The amount of 
shed Met ectodomain fragments has been significantly correlated with the potential for 
malignancy [90]. Moreover, ectodomain shedding of Met can be induced by EGFR ligands, 
and HGF in turn is able to transactivate EGFR followed by enhanced activation of ERK or 
PI3-K pathways [91]. Schirrmeister et al. showed that infection with H. pylori provokes a 
shedding of the surface proteins of Met through a disintegrin and metalloprotease family of 
proteases, ADAM10 [92], which explains the CagA independent mechanism for Met-
dependent phenotypes after H. pylori infection. 
These published data suggest that HGF-induced activation of Met in gastric epithelial 
cells has an anticipated impact on H. pylori-related gastric diseases, which includes gastric 
cancer. However, a logical model of HGF and H. pylori-induced Met signal transduction has 
been presented [93]. The molecular interactions included in the model were all assembled 
manually based on meta-analysis of published experimental results. This model reveals the 
differences and commonalities in the response of the network upon HGF and H. pylori-
induced Met signaling. Their data indicated that PLCγ1 represents a key factor in H. pylori-
induced ERK activation. Inhibition of ERK1/2, which is critically important for the induction 
of cell scattering in H. pylori-infected epithelial cells, could represent a target for the 
treatment of invasive stomach cancers caused by H. pylori infection. Moreover, in light of 
their observation that the activation of ERK by HGF is not influenced by a PLCγ1 inhibition, 
the use of specific pharmaceutical inhibitors for PLCγ1 might thus represent a promising 
therapeutic strategy to prevent the pathogenic effects of H. pylori infection. This is an 
interesting approach to host-pathogen systems biology that aims to decipher the signaling 
changes brought about by pathogenic bacteria, which could provide an in silico prediction of 
a relevant target against pathogen infection. In addition, McCracken et al. recently developed 
a de novo generation of three-dimensional human gastric organoids in vitro via the directed 
differentiation of human pluripotent stem cells [94]. Using human gastric organoids to model 
the pathogenesis of human disease, they demonstrated that H. pylori infection resulted in a 
	 9 
rapid association of the virulence factor CagA with Met, the activation of signaling, and the 
induction of epithelial proliferation, and presents a new in vitro system to elucidate the 
mechanisms underlying stomach development and disease. This model is also useful for the 
screening of efficient therapeutic drugs. 
Various species of Helicobacter have been described in animals. It has been suggested 
that cats and dogs could act as animal reservoirs in the transmission of H. heilmannii and 
other Helicobacter species to humans. In humans, similar to H. pylori, H. heilmannii 
accompanies the pathogenesis of chronic gastritis, peptic ulcer disease, gastric cancer and 
mucosa-associated lymphoid-tissue lymphoma. Met immunoreactivity has been found in the 
lymphocytes composing the mucosa associated with lymphoid-tissue lymphoma following 
oral administration of H. heilmannii to mice, and HGF immunoreactivity has been recognized 
mostly in the endothelial cells and macrophages in the mucosa-associated lymphoid-tissue 
lymphoma [95]. Moreover, the administration of either the antibody against Met or Met 
inhibitor to infected mice has induced a significant suppression of the mucosa-associated 
lymphoid-tissue lymphoma lymphomagenesis in mucosa-associated lymphoid-tissue 
lymphoma after H. heilmannii infection. 
 
Listeria infection and Met signaling 
Listeria monocytogenes (L. monocytogenes) is a foodborne pathogen responsible for 
human listeriosis, a systemic infection with a 30% mortality rate [96]. Upon ingestion, L. 
monocytogenes not only can survive and multiply in the intestinal lumen, it can also cross the 
blood–brain barrier and cause meningitis and encephalitis, and it can cross the placental 
barrier, which can result in abortion and neonatal infection [97]. The ability of L. 
monocytogenes to cross these host barriers relies on its capacity to invade nonphagocytic 
cells. This ability is mediated by two bacterial surface proteins: internalin (Inl) A and B [98]. 
InlB is an L. monocytogenes surface protein noncovalently bound to its cell wall. 
Surprisingly, it was reported that InlB interacts with Met [34] (Fig. 4). The binding of InlB to 
Met mimics HGF signaling and induces membrane ruffling and cell scattering via the 
activation of the PI3-K, which is a process critical for internalization of L. monocytogenes 
[99]. Further analysis demonstrated that intestinal target cells of L. monocytogenes exhibit a 
constitutive PI3-K activity, rendering InlB dispensable for InlA-dependent intestinal barrier 
crossing of L. monocytogenes. In contrast, the placental barrier does not exhibit constitutive 
PI3-K activity, which means the InlB-Met pathway is necessary for InlA-dependent L. 
monocytogenes placental invasion [100]. InlB protein has an N-terminal cap region, a leucine-
rich repeat domain, an interrepeat Ig-like (IR) region, a B-repeat, and three C terminal GW 
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modules (which are 80 amino acid repeats that start with the amino acid sequence GW). The 
structure presented by Niemann et al. indicated that the leucine-rich repeat domain of InlB 
binds strongly to the first Ig-like domain of Met while maintaining flexibility in the Met N-
terminal Sema domain [101]. They also showed that the interaction between the IR domain of 
InlB and Met is critical for the further activation of Met. As the IR domain alone cannot bind 
to Met, the interaction between the leucine-rich repeat and Met would serve as a docking site, 
allowing the IR-Sema interaction that promotes Met activation. Interestingly, the HGF (β-
chain)-binding sites for Met do not overlap those of InlB. Despite the fact that InlB is not 
structurally related to HGF, and that HGF and InlB bind to different regions in Met and 
induce different Met conformations, InlB has the potential to induce very similar signaling 
pathways to HGF after Met activation [102]. 
The potential of InlB to activate Met without competition to HGF allows the application 
of InlB as an HGF mimic. Mungunsukh et al. engineered a head-to-tail repeat of fragments of 
the InlB protein from amino acids 36-321 with a linker peptide (2xInlB 36-321) [103]. They 
demonstrated that this tandem dimmer induces signaling through ERK1/2, PI3-K/Akt, and 
STAT3 pathways, and has improved migratory activity. This linker peptide also induces 
proliferation in primary lung cells equivalent to full-length HGF. In a similar manner, Kolditz 
et al. used structure-based engineering to introduce two intermolecular disulfide bonds into 
InlB321, resulting in a dimeric protein with a two-fold (C2) symmetry, which is referred to as 
the InlB321-crystal dimer. In contrast to HGF, the InlB321-crystal dimer is a non-
glycosylated protein, and large-scale production can easily be accomplished in Escherichia 
coli. InlB321-crystal dimer elicited the same response as HGF in terms of mitogenic and 
motogenic effects on human keratinocytes. To facilitate its application as a therapeutic drug 
for dermal wounds, they developed a hydroxyethyl cellulose gel that could be an appropriate 
vehicle for InlB321-crystal dimer with regard to its stability [104]. 
 
HGF and uropathogenic Escherichia coli (E. coli) infection 
The urinary tract is frequently the source of E. coli bacteremia. Bacteria from the 
urinary tract must cross an epithelial layer to enter the bloodstream. The epithelium plays a 
central role in host defenses against pathogens. Using an in vitro model of epithelial tissue, 
Wu et al. demonstrated that a loss of epithelial polarity by HGF treatment reduces the ability 
of renal epithelium to resist invasion by J96, the uropathogenic strain of E. coli. This suggests 
that although HGF seems to be important in the process of epithelial organ regeneration, it 
may also transiently compromise an organ’s resistance to bacterial invasion [105]. 
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HGF signaling and Pseudomonas aeruginosa-induced keratitis 
Pseudomonas aeruginosa (P. aeruginosa) is a gram-negative bacterium that is one of 
the most common keratitis-inducing microbial isolates. Jiang et al. reported that HGF 
signaling impacts the severity of P. aeruginosa keratitis. They established important 
regulatory roles for HGF, the levels of which appear critical to Met signaling, downstream 
mammalian targeting of rapamycin (mTOR) regulation (promoting or inhibiting), and disease 
outcome [106]. HGF signaling through Met, if not balanced, results in enhanced P. 
aeruginosa-induced keratitis, whether that balance is manipulated by recombinant HGF 
application, or by the rapamycin inhibition of mTOR. 
 
HGF-Met pathway and viral infectious diseases 
Kaposi sarcoma-associated herpes virus is a principal causative agent of Kaposi 
sarcoma and primary effusion lymphoma, which arises preponderantly in 
immunocompromised individuals, particularly patients with acquired immune deficiency 
syndrome (AIDS). Kaposi sarcoma is the most frequent type of malignant lesion in patients 
with AIDS, even after the widespread use of combination antiretroviral therapy, and it is 
characterized by spindle cell proliferation, inflammatory cell infiltration, angiogenesis, 
edema, and invasiveness [107,108]. Tadeschi et al. evaluated the plasma concentrations of 
selected cancer-associated inflammatory and immune-modulated cytokines in HIV-positive 
patients with advanced Kaposi sarcoma and reported that plasma HGF is among the 
candidates for a novel predictor of clinical responses during combination antiretroviral 
therapy in HIV-positive Kaposi sarcoma patients [109]. In addition, Dai et al. reported that 
the HGF-Met pathway is highly activated by Kaposi sarcoma-associated herpes virus in vitro 
and in vivo [110]. They also demonstrated that selective Met inhibitor PF-2341066 can induce 
apoptosis of primary effusion lymphoma via cell-cycle arrest and DNA damage, and it has 
suppressed tumor progression in a xenograft murine model. 
Adult T-cell leukemia (ATL) is an intractable malignancy of CD4 T cells that is 
etiologically associated with infection by human T-cell leukemia virus-type I. Most 
individuals in the chronic stage of Adult T-cell leukemia eventually undergo progression to a 
highly aggressive acute stage. Choi et al. isolated CD4 cells from individuals in the chronic or 
acute stages of Adult T-cell leukemia and profiled their gene expressions using DNA 
microarrays [111]. Met gene expression was specific to the acute stage of Adult T-cell 
leukemia, and the plasma concentration of HGF was increased in individuals in either the 
acute or chronic stage. They further described how HGF induces the proliferation of a Met-
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positive Adult T-cell leukemia cell line, and how this effect can be blocked by antibodies 
against HGF. 
Hepatocellular carcinoma is the most common form of liver cancer worldwide, and 
chronic infection with hepatitis B virus (HBV) is one of the major causes. HBV infection 
causes chronic liver inflammation, subsequent cirrhosis, and, ultimately, malignant 
progression to hepatocellular carcinoma. Studies using Met Tg mice have demonstrated that 
overexpression of Met alone is sufficient to promote the development of hepatocellular 
carcinoma [112,113], which suggests the pathological significance of the HGF-Met pathway 
in hepatocellular carcinoma. Consistently, Ozden et al. have shown that serum HGF levels in 
patients with chronic hepatitis B reflects the viral load, necro-inflammatory activity in the 
liver, and the degree of structural progression [114]. Elevated levels of HGF and EGF have 
been found in HBV-infected individuals, and these growth factors are known to stimulate 
survival signaling in primary human hepatocytes [115]. Notably, Xie et al. reported that liver 
tumors from human HGF transgenic (Tg) mice have gene expression patterns that are 
virtually the same as those from HBV-positive hepatocellular carcinoma patients, which 
corresponds to patients with a poor prognosis [116]. These findings suggest that HGF or 
HGF-Met signaling markers are crucial determinants in generating hepatocellular carcinoma 
and in predicting sensitivity to Met inhibitors. 
Hepatitis C virus (HCV) is involved in the initiation and progression of liver fibrosis by 
regulating genes encoding host proteins. Zhu et al. discovered that cellular microRNA miR-
16 levels were increased in patients with HCV infection and were inversely correlated with 
HGF and Smad7 expression levels in those patients [117]. A human liver cell line infected 
with an Ad-HCV core adenovirus (coding for the first 191 amino acids of the HCV 
polyprotein corresponding to the HCV core protein) continued to show upregulated levels of 
miR-16 associated with decreased expressions of HGF and Smad7. Additionally, interferon-α 
(IFN-α) could reverse the changes in gene expression induced by HCV infection. These 
results suggest that the upregulation of miR-16 expression induced by HCV infection is a 
novel mechanism that contributes to the downregulation of HGF and Smad7 in the 
development of liver fibrosis. 
Collectively, the HGF-Met system plays an important role in many infectious diseases 
that share similarities with conditions such as cancer, tissue injury, cardiovascular disease, 
neurodegenerative disease, and auto-immune diseases. The monitoring of HGF and Met 
expression, along with real-time detection of Met activation, can be a beneficial biomarker of 
these infectious diseases in terms of diagnosis and/or prediction of disease progression. 
Although the HGF-Met system is somewhat of a double-edged sword in infectious diseases, 
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manipulating the HGF-Met system with complete control, either positive or negative, can 
systemically and/or locally (topically) lead to a tailor‐made treatment for those infectious 
diseases. 
To mimic HGF stimulation, the macrocyclic peptide capable of activating Met was 
discovered [118]. The monomeric macrocyclic peptides are capable of high-affinity binding 
to the Met, but neither activate Met nor inhibit HGF-induced Met activation. However, 
dimerization of these peptides conferred them with Met agonistic activity. Dimerized 
macrocyclic peptides selectively activate Met and exert Met-mediated typical and unique 
biological activities that are mitogenic, motogenic (enhancement of cell motility), and 
morphogenic (induction of blanching tubulogenesis). The maximal activities of dimerized 
macrocyclic peptides are indistinguishable to HGF. The current library of research promotes 
the clinical application of these small HGF-mimicking peptides, as well as the development 
of alternative technologies for the production of non-protein regenerative medicines for broad 
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Table 1. Physiological roles of HGF deduced from conditional knockout mice 
 
Met−/− Tissue/Cell Types Characteristics Ref. 
Liver 
Hepatocytes 
Highly susceptible to apoptosis after liver injury 
[13] 
Impairment in recovery from liver necrosis after liver injury 
Impairment in Erk1/2 activation and G2/M transition after liver injury [14] 
Hepatocytes 
Steatotic change of the liver in aged mice 
[15] Decrease in mitotic hepatocytes after partial hepatectomy 
Delayed regeneration after partial hepatectomy 
Hepatocytes 
Promoted liver fibrosis after liver injury [16] 
Extensive necrosis and lower proliferation of hepatocytes after bile-duct 
ligation 
[17] 
Enhanced susceptibility to liver fibrosis  
Oval cells 
Decrease in oval cell viability and more prone to apoptosis [18] 
Reduction in oval cell pool 
[19] 
Impairment in migration and differentiation into hepatocytes 
Kidney 
Tubular cells 
No appreciable defect in kidney morphology and function 
[20] 
Aggravated renal injury and inflammation after acute kidney injury 
Podocytes 
Neither albuminuria nor overt pathologic lesions 
[21] 
Severe podocyte injury and apoptosis, and albuminuria after toxic injury 
Collecting duct 
Increased fibrosis and tubular necrosis after unilateral ureteral 
obstruction [22] 
Reduced capacity in regeneration after release of the obstruction 
Ureteric bud 
Double knockout of Met and EGF receptor in ureteric bud 
[23] 
Decrease in branching and a reduction in final glomerular number 
Skin 
Keratinocytes 
Lack of keratinocyte migration after skin wound 
[24] 
Severe impairment epidermal wound closure 
Pancreas 
β-Cell 
Mild hyperglycemia, and decreased serum insulin levels at 6 months 
[25] Loss of acute-phase insulin secretion in response to glucose, and impaired 
glucose tolerance 
Diminished glucose tolerance and reduced plasma insulin after a glucose 
challenge 
[26] 
Normal glucose and β-cell homeostasis 
[27] 
Susceptible to streptozotocin-induced diabetes 
Nervous System 
Ganglionic eminence 
Increased numbers of striatal GABAergic interneurons in the lateral 
sensorimotor 
[28] 
Areas with distinct behavioral deficits 
Delayed procedural learning 
Cerebral cortex  Larger size in the rostral cortex, caudal hippocampus, dorsal striatum, [29] 
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and hippocampus thalamus, and corpus callosum 
Dorsal pallial 
Increases proximal and reduces distal apical dendritic branching of 
neocortical pyramidal neurons in post-pubertal period 
[30] 
Forebrain neurons 
Reduced volume of cortical tissue 
[31] Increase in spine head volume, but no change in density of spines 
Hyperconnectivity in circuit-specific intracortical neurons 
Heart 
Cardiomyocytes 
Normal heart development 
[32] Cardiomyocyte hypertrophy and interstitial fibrosis by 6 months 
Systolic cardiac dysfunction by 9 months 
Immune System 
Dendritic cells 
Impaired emigration toward draining lymph nodes upon inflammation-
induced activation [33] 








Two-pronged roles of HGF in tissue regeneration and cancer tissues. HGF is mainly 
expressed in stromal cells. Cells responding to HGF are conceptually shown in green. 
Dynamic morphogenesis (e.g., blanching tubulogenesis in renal tubular cells) and promotion 
of cell survival (e.g., for neurons) mediated by the HGF–Met pathway play roles in tissue 
regeneration after tissue injury (right portion). Dynamic cell movement and survival 
promoted by Met activation participate in invasion-metastasis and resistance to anticancer 







Schematic structures of HGF (A) and Met (B). A single-chain HGF is cleaved between 
Arg494 and Val495 by serine proteases and HGF is modified by glycosylation. Domain 





Molecular mechanisms responsible for the promotion of cell survival (suppression of death-






Hijack HGF-Met pathway. Bacterial protein InlB (Listeria monocytogenes) or CagA 
(Helicobacter pylori) deregulates Met downstream signaling, which creates a suitable 
environment for infection. 
